NeoGenomics Second Quarter 2025 Earnings: EPS Misses Expectations

NeoGenomics (NASDAQ:NEO) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$181.3m (up 10% from 2Q 2024).
• Net loss: US$45.1m (loss widened by 142% from 2Q 2024).
• US$0.35 loss per share (further deteriorated from US$0.15 loss in 2Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

NeoGenomics EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 102%.

Looking ahead, revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 23% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 1 warning sign for NeoGenomics you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.